Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474029 | 1.00 | ALDH1A1 (0.35) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL15474058 | 0.87 | ALDH1A1 (0.35) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL2592112 | 0.87 | ALDH1A1 (0.35) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL15693440 | 0.87 | ALDH1A1 (0.37) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL15693442 | 0.87 | ALDH1A1 (0.37) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL15578429 | 0.86 | ALDH1A1 (0.36) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL2584473 | 0.82 | ALDH1A1 (0.38) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL12272762 | 0.82 | ALDH1A1 (0.38) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL15722223 | 0.82 | ALDH1A1 (0.42) | ALDH1A1GAATHRBHTTL3MBTL1 | |
| SCHEMBL2591505 | 0.82 | ALDH1A1 (0.42) | ALDH1A1GAATHRBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748418-B2 | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | ALDH1A1 485/4885GAA 40/4885THRB 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.